Effects of etoposide (VP16) on vertebrate retinal function

Journal of Toxicology - Cutaneous and Ocular Toxicology

Volumn 18, Issue 1, 1999, Pages 23-32

  Lüke, Christoph ^a   Bartz Schmidt, Karl U ^b   Walter, Peter ^b   Thumann, Gabriele ^b   Brunner, Richard ^b   Michel, Olaf ^b   Sickel, Werner ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FOSCARNET; GANCICLOVIR;

ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; CYTOMEGALOVIRUS; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SAFETY; ELECTRORETINOGRAM; EYE TOXICITY; HUMAN; HUMAN TISSUE; INTRAVITREAL DRUG ADMINISTRATION; ISOLATED RETINA; NONHUMAN; RETINA INJURY; VIRUS INHIBITION;

ANIMALIA; BOVINAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; VERTEBRATA;

EID: 0344959449     PISSN: 07313829     EISSN: None     Source Type: Journal    
DOI: 10.3109/15569529909049321     Document Type: Article

References (38)

1. A. G. Palestine, M. M. Rodrigues, and A. M. Macher, Ophthalmic involvement in acquired immunodeficiency syndrome, Ophthalmology 91: 1092, 1984.
2. W. R. Freeman, C. W. Lerner, and J. A. Mines, A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome, Am. J. Ophthalmol. 97: 133, 1984.
3. G. N. Holland, J. S. Pepose, T. H. Pettit, M. S. Gottlieb, R. D. Yee, and R. Y. Roos, Acquired immune deficiency syndrome, ocular manifestations, Ophthalmology 90: 859, 1983.
4. K. U. Bartz-Schmidt, B. Kirchhof, K. Lemmen, and K. Heimann, Ocular manifestations of AIDS, Z. Prakt. Augenheilkd. 17: 181, 1996.
5. W. R. Freemann, J. I. Quiceno, J. A. Crapotta, A. Listhaus, D. Munguia, and M. F. Aguilar, Surgical repair of rhegmatogenous retinal detachment in immunosuppressed patients with cytomegalovirus retinitis, Ophthalmology 99: 466, 1992.
6. D. A. Jabs, C. Enger, J. Haller, and S. de Bustros, Retinal detachments in patients with cytomegalovirus retinitis, Arch. Ophthalmol. 109: 794, 1991.
7. I. Cochereau-Massin, P. Lehoang, and M. Lautier-Frau, Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome, Ophthalmology 98: 1348, 1991.
8. W. L. Drew, D. Ives, and J. P. Lalezari, Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS, Syntex Cooperative Oral Ganciclovir Study Group, N. Engl. J. Med. 333: 615, 1995.
9. D. F. Martin, D. J. Parks, and S. D. Mellow, Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial, Arch. Ophthalmol. 112: 1531, 1994.
10. D. E. Henderly, W. R. Freeman, D. M. Causey, and N. A. Rao, Cytomegalovirus retinitis and response to therapy with ganciclovir, Ophthalmology 94: 425, 1987.
11. D. A. Jabs, C. Newman, S. DeBustros, and B. F. Polk, Treatment of cytomegalovirus retinitis with ganciclovir, Ophthalmology 94: 824, 1987.
12. P. Le hoang, B. Girard, and M. Robinet, Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome, Ophthalmology 96: 865, 1989.
13. B. D. Kuppermann, J. I. Quiceno, and M. Flores-Aguilar, Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy, J. Infect. Dis. 168: 1506, 1993.
14. R. V. Farese, M. Schambelan, H. Hollander, S. Stringari, and M. Jacobson, Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis, Ann. Intern. Med. 112: 955, 1990.
15. M. M. Fanning, S. E. Read, M. Benson, S. Vas, and A. Rachlis, Foscarnet therapy of cytomegalovirus retinitis in AIDS, J. Acquir. Immune Defic. Syndrome 3: 472, 1990.
16. P. Chrisp and S. P. Clissold, Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis, Drugs 41: 104, 1991.
17. A. Erice, S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, and M. C. Jordan, Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients, N. Engl. J. Med. 320: 289, 1989.
18. M. A. Jacobson, W. L. Drew, and J. Feinberg, Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS, J. Infect. Dis. 163: 1348, 1991.
19. K. K. Knox, W. R. Drobyski, and D. R. Carrigan, Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient [letter], Lancet, 337: 1292, 1991.
20. D. A. Jabs, J. P. Dunn, C. Enger, M. Forman, N. Bressler, and P. Charache, Cytomegalovirus retinitis and resistance. Prevalence of resistance at diagnosis, Arch. Ophthalmol. 114: 809, 1996.
21. W. L. Drew, R. C. Miner, and D. F. Busch, Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection, J. Infect. Dis. 163: 716, 1991.
22. J. D. Benson and E. S. Huang, Human cytomegalovirus induces expression of cellular topoisomerase II, J. Virol. 64: 9, 1990.
23. J. D. Benson and E. S. Huang, Two specific topoisomerase II inhibitors prevent replication of human cytomegalovirus DNA: An implied role in replication of the viral genome, J. Virol. 62: 4797, 1988.
24. E. S. Huang, J. D. Benson, S. M. Huong, B. Wilson, and C. van der Horst, Irreversible inhibition of cytomegalovirus replication by topoisomerase II inhibitor, etoposide: A new strategy for the treatment of human cytomegalovirus infection, Antiviral Res. 17: 17, 1992.
25. G. H. Small, G. A. Peyman, A. Srinivasan, R. T. Smith, and R. Fiscella, Retinal toxicity of combination antiviral drugs in an animal model, Can. J. Ophthalmol. 22: 300, 1987.
26. G. W. Kao, G. A. Peyman, R. Fiscella, and B. House, Retinal toxicity of ganciclovir in vitrectomy infusion solution, Retina 7: 80, 1987.
27. G. A. Peyman and J. A. Schulman, Intravitreal drug therapy, Jpn. J. Ophthalmol. 33: 392, 1989.
28. Y. Shirao and K. Kawasaki, Retinal toxicology study using electrophysiological methods in rabbits, In Ocular Toxicology, I. Weisse, O. Hockwin, K. Green, R. C. Tripathi, Eds., Plenum Press, New York, 1995, p. 27.
29. W. Sickel, Retinal metabolism in dark and light, In, Handbook of Sensory Physiology, Vol. VII/2, M. G. F. Fuortes, Ed., Springer, Berlin/Heidelberg/New York, 1972, p. 667.
30. P. Walter, C. Lüke, and W. Sickel, Effects of clindamycin on neural function in the isolated perfused vertebrate retina, In Ocular Toxicology, I. Weisse, O. Hockwin, K. Green, R. C. Tripathi, Eds., Plenum Press, New York, 1995, p. 63.
31. T. Furukawa and I. Hanawa, Effects of some cations on electroretinogram of the toad, Jpn. J. Physiol. 5: 289, 1955.
32. W. Haschke and W. Sickel, Das Elektroretinogramm des Menschen bei Ausfall der Ganglienzellen und partieller Schädigung der Bipolaren, Acta Ophthalmol. Suppl. 70: 164, 1962.
33. G. A. Peyman, D. Greenberg, and G. A. Fishman, Evaluation of toxicity of intravitreal antineoplastic drugs, Ophthalm. Surg. 15: 411, 1984.
34. J. Mills, M. A. Jacobson, and J. J. O'Donnell, Treatment of cytomegalovirus retinitis in patients with AIDS, Rev. Infect. Dis. 10(Suppl. 3): 522, 1988.
35. J. P. Lalezari, Cidofovir: A new therapy for cytomegalovirus retinitis, J. Acquir. Immune Defic. Syndrome 14 (Suppl. 1): 22, 1997.
36. J. S. Pepose, C. Newman, and M. C. Bach, Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir, Ophthalmology 94: 414, 1987.
37. D. J. D'Amico, J. H. Talamo, and D. Felsenstein, Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U, Arch. Ophthalmol. 104: 1788, 1986.
38. L. H. Einhorn, K. Pennington, and J. McClean, Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology group study, Semin. Oncol. 17: 32, 1990.